Trygg Pharma acquires factory in the UK
Trygg Pharma acquires a manufacturing facility from Lundbeck Pharmaceuticals Ltd. for DKK 120 million. The site is located in Seal Sands, Middlesbrough, UK, reports www.megafishnet.com with reference to Aker Biomarine.
The purchase of the facility in the UK is a step to increase the company・s manufacturing capacity further after the acquisition of EPAX AS from Austevoll Seafood ASA in November 2010.
The transaction is expected to close July 1st 2011, subject to remaining due diligence.
For further questions, please contact Terje Bakken, incoming CEO, +47 906 54 227
About Trygg Pharma:
Trygg Pharma is a Norwegian‐based 50/50 joint venture between Aker BioMarine ASA and Lindsay Goldberg LLC. Trygg Pharma is a leading manufacturer of marine‐based omega‐3 EPA/DHA concentrates for nutraceutical and pharmaceutical applications. EPAX, a subsidiary of Trygg Pharma, is a long‐standing leader in marine‐based omega‐3 EPA/DHA fatty acid concentrates for nutraceutical manufacturers and marketers, with a focus on the high concentrate segment. Trygg Pharma is completing a clinical Phase III study on an omega‐3 based drug candidate for hypertriglyceridemia.